id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2010-D-0482-0033,FDA,FDA-2010-D-0482,"Guidances for Industry and Investigators; on Safety Reporting Requirements for Investigational New Drug Applications and Bioavailability/ Bioequivalence Studies, and a Small Entity Compliance Guide; Availability",Notice,Notice of Availability,2012-12-20T05:00:00Z,2012,12,2012-12-20T05:00:00Z,,2019-08-22T20:02:45Z,2012-30651,0,0,0900006481193abb
FDA-2010-D-0482-0034,FDA,FDA-2010-D-0482,Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA BE Studies,Other,Guidance,2012-12-20T05:00:00Z,2012,12,2012-12-20T05:00:00Z,,2024-11-12T05:10:37Z,,1,0,0900006481193beb
FDA-2010-D-0482-0035,FDA,FDA-2010-D-0482,"Guidances for Industry and Investigators; on Safety Reporting Requirements for Investigational New Drug Applications and Bioavailability/ Bioequivalence Studies, Small Entity Compliance Guide",Other,Guidance,2012-12-20T05:00:00Z,2012,12,2012-12-20T05:00:00Z,,2019-08-22T20:06:38Z,,0,0,0900006481193bed
FDA-2010-D-0482-0032,FDA,FDA-2010-D-0482,"Minute of the FDA-PhRMA Dialogue, dated September 9, 2011",Other,Minutes,2012-04-13T04:00:00Z,2012,4,2012-04-13T04:00:00Z,,2019-08-22T20:02:30Z,,0,0,0900006480feea00